HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IMCR
Immunocore Holdings plc
IMCR lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IMCR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
IMCR's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IMCR PE Valuation
IMCR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IMCR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
IMCR has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IMCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.66 | -$0.09 |
| Q2 2026 | -$0.38 | +$0.02 |
| Q1 2026 | -$0.56 | -$0.13 |
| Q4 2025 | -$0.71 | +$0.31 |
| Q3 2025 | -$0.57 | +$0.41 |
| Q2 2025 | -$0.40 | +$0.70 |
| Q1 2025 | -$0.43 | +$0.82 |
| Q4 2024 | -$1.02 | +$0.21 |
IMCR has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IMCR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over IMCR on profitability, with a higher operating margin.
IMCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $102.2M | -1.4% |
| Q2 2026 | $115.9M | +18% |
| Q1 2026 | $106.7M | +14% |
| Q4 2025 | $104.5M | +24% |
| Q3 2025 | $103.7M | +29% |
| Q2 2025 | $98M | +30% |
| Q1 2025 | $93.9M | +33% |
| Q4 2024 | $84.1M | +13% |
IMCR's revenue is growing: $102M last quarter, down 1.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -13% | -6.4 points |
| Q2 2026 | -2.6% | +13 points |
| Q1 2026 | 6.8% | +11 points |
| Q4 2025 | -19% | +4.3 points |
| Q3 2025 | -6.9% | +3.7 points |
| Q2 2025 | -15% | +6.1 points |
| Q1 2025 | -3.9% | +34 points |
| Q4 2024 | -23% | +1.2 points |
IMCR's operating margin was −13% last quarter, down 6.4 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IMCR on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $17.7M | +$22.9M |
| Q2 2026 | $15.1M | -41% |
| Q1 2026 | -$15.6M | -11455% |
| Q4 2025 | -$35.5M | -$18M |
| Q3 2025 | -$5.2M | -126% |
| Q2 2025 | $25.6M | +10% |
| Q1 2025 | $137K | +$5.2M |
| Q4 2024 | -$17.5M | +$1M |
IMCR has burned cash in most quarters: −$18M over the past year, against $3M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IMCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IMCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +585K shares |
| 1 year | +2.3% | +1.2M shares |
| 3 years | -4.8% | -2.6M shares |
| 5 years | +18% | +7.8M shares |
| Available history | +89% | +24.3M shares |
IMCR has 52M diluted shares, up 2.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IMCR Net Leverage
IMCR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IMCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 30.2 | Neutral |
IMCR's weekly RSI is 45 (neutral) and its Stochastic is 30 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IMCR PE vs Healthcare Sector
IMCR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IMCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $30.3 | 0.7% above |
| 20 week MA | $32.6 | 6.6% below |
| 50 week MA | $32.1 | 5% below |
| 100 week MA | $32.1 | 5.1% below |
| 200 week MA | $42.0 | 27% below |
IMCR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IMCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $43.2 | $35.4 | -18% |
| 2022 | $35.4 | $57.8 | +63% |
| 2023 | $57.8 | $68.3 | +18% |
| 2024 | $68.3 | $29.2 | -57% |
| 2025 | $29.2 | $36.1 | +24% |
| 2026 YTD | $36.1 | $30.5 | -16% |
IMCR has the edge over HIMS on returns for 2026, with the stronger performance.